Matthias Schaier, Florian Kälble, Louise Benning, Paula Reichel, Christoph Mahler, Christian Nusshag, Jonas Rusnak, Tobias Gutting, Michael Preusch, Martin Zeier, Christian Morath, Claudius Speer
{"title":"ANCA-associated vasculitis and the impact of diffuse alveolar hemorrhage in elderly patients: a retrospective cohort study.","authors":"Matthias Schaier, Florian Kälble, Louise Benning, Paula Reichel, Christoph Mahler, Christian Nusshag, Jonas Rusnak, Tobias Gutting, Michael Preusch, Martin Zeier, Christian Morath, Claudius Speer","doi":"10.1007/s00296-025-05812-8","DOIUrl":null,"url":null,"abstract":"<p><p>The ANCA-associated vasculitis (AAV) has an exceptionally high morbidity and mortality especially in patients with diffuse alveolar hemorrhage (DAH). Data on DAH in elderly AAV patients is still very limited. To investigate the impact of DAH on patient survival, relapse-free survival, death from infectious complications, and the incidence of pneumonia in one of the most vulnerable but often underrepresented AAV subpopulation-elderly patients. We included 139 AAV patients in this retrospective cohort study and performed a 5-year follow-up. AAV patients were divided into patients ≤ 65 and > 65 years (\"elderly\"). Elderly AAV patients were further subdivided into patients with and without DAH. Relapse-free survival was comparable (P = 0.49) whereas overall patient survival (P = 0.01) was significantly lower in patients > 65 as compared to ≤ 65 years. Death due to infectious complications occurred more frequently in the elderly cohort (log-rank P = 0.02). Especially the incidence of pneumonia (including opportunistic pathogens) was considerably higher in elderly AAV patients (log-rank P = 0.001). Overall survival in elderly patients was significantly lower in patients with as compared to patients without DAH [8/18 (44%) versus 9/52 (17%) deaths (P = 0.02)] while relapse-free survival was again comparable (P = 0.87) between both groups. Notably, 6 out of 8 fatal outcomes in elderly DAH patients were associated with severe infections. In multivariate analyses, age and glucocorticoid (GC) dose at 3 months were the only predictors of death from infectious complications, whereas this could not be independently demonstrated for DAH. Life-threatening infections with (opportunistic) pneumonia are common in elderly AAV patients with DAH during the first 12 months and higher GC dose was an independent predictor of death from infectious complications.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 3","pages":"68"},"PeriodicalIF":3.2000,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11876205/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rheumatology International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00296-025-05812-8","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
The ANCA-associated vasculitis (AAV) has an exceptionally high morbidity and mortality especially in patients with diffuse alveolar hemorrhage (DAH). Data on DAH in elderly AAV patients is still very limited. To investigate the impact of DAH on patient survival, relapse-free survival, death from infectious complications, and the incidence of pneumonia in one of the most vulnerable but often underrepresented AAV subpopulation-elderly patients. We included 139 AAV patients in this retrospective cohort study and performed a 5-year follow-up. AAV patients were divided into patients ≤ 65 and > 65 years ("elderly"). Elderly AAV patients were further subdivided into patients with and without DAH. Relapse-free survival was comparable (P = 0.49) whereas overall patient survival (P = 0.01) was significantly lower in patients > 65 as compared to ≤ 65 years. Death due to infectious complications occurred more frequently in the elderly cohort (log-rank P = 0.02). Especially the incidence of pneumonia (including opportunistic pathogens) was considerably higher in elderly AAV patients (log-rank P = 0.001). Overall survival in elderly patients was significantly lower in patients with as compared to patients without DAH [8/18 (44%) versus 9/52 (17%) deaths (P = 0.02)] while relapse-free survival was again comparable (P = 0.87) between both groups. Notably, 6 out of 8 fatal outcomes in elderly DAH patients were associated with severe infections. In multivariate analyses, age and glucocorticoid (GC) dose at 3 months were the only predictors of death from infectious complications, whereas this could not be independently demonstrated for DAH. Life-threatening infections with (opportunistic) pneumonia are common in elderly AAV patients with DAH during the first 12 months and higher GC dose was an independent predictor of death from infectious complications.
期刊介绍:
RHEUMATOLOGY INTERNATIONAL is an independent journal reflecting world-wide progress in the research, diagnosis and treatment of the various rheumatic diseases. It is designed to serve researchers and clinicians in the field of rheumatology.
RHEUMATOLOGY INTERNATIONAL will cover all modern trends in clinical research as well as in the management of rheumatic diseases. Special emphasis will be given to public health issues related to rheumatic diseases, applying rheumatology research to clinical practice, epidemiology of rheumatic diseases, diagnostic tests for rheumatic diseases, patient reported outcomes (PROs) in rheumatology and evidence on education of rheumatology. Contributions to these topics will appear in the form of original publications, short communications, editorials, and reviews. "Letters to the editor" will be welcome as an enhancement to discussion. Basic science research, including in vitro or animal studies, is discouraged to submit, as we will only review studies on humans with an epidemological or clinical perspective. Case reports without a proper review of the literatura (Case-based Reviews) will not be published. Every effort will be made to ensure speed of publication while maintaining a high standard of contents and production.
Manuscripts submitted for publication must contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in an appropriate version of the 1964 Declaration of Helsinki. It should also be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted.